Search
Treatment of acute lymphoblastic leukemia by activation of patient's immune cells by a bispecific antibody.
Abstract S722
Acute lymphoblastic leukemia (ALL) is a rare type of blood cancer which is mainly treated by intensive chemotherapy.
EHA returns to Cairo with the Highlights of the 24th EHA Congress
The 4th Highlights of Past EHA (HOPE) Middle East & North Africa (MENA) took place (for the third time) in Cairo, Egypt, organized in collaboration with the Pan Arab Hematology Association (PAHA) and hosted by the Egyptian Society of Hematology…
Read moreUrgent action needed to avoid widespread shortage of in-vitro diagnostic tests
In a new statement, BioMed Alliance highlights its increasing concern about the availability of In Vitro Diagnostic (IVD) testing devices in Europe.
Read moreThe ‘i4MDS’ consortium looks to the future at its second general meeting
The International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—also known as ‘i4MDS’—held its second general meeting in The Hague from February 9–10, 2024.
Read morePrivacy statement
May 21, 2021
Privacy Statement European Hematology Association
Personal Data is processed in the context of the services provided by European Hematology Association (hereinafter also; “EHA”).
EHA, in partnership with ISTH, award two fellows to support global educational opportunities
EHA and the International Society on Thrombosis and Hemostasis (ISTH) jointly awarded two joint ISTH-EHA Training Fellowships to Araci Rondon (The Netherlands) and Dianne van der Wal (Australia).
Read moreEHA-Baltic Hematology Tutorial in Estonia provides European-level expertise to local hematologists
EHA partnered with three Baltic societies on October 18 and 19 to provide European-level expertise to local hematology trainees and experienced hematologists.
Read moreTreatment, medicine and hematology research: What patients want and doctors need (to know)
Jan Geissler, a Patient Advocate remarked about the Congress: “Over and above scientific updates, much can be achieved in partnership between hematologists and patients.
Read more100,000 Patient data sets: The value of data sharing to accelerate blood cancer research.
With almost 100,000 patient data sets identified and 63,000 already transferred to the HARMONY Big Data Platform, the HARMONY Alliance is fully equipped to facilitate state-of-the-art research into blood cancers.
Read moreHelping to shape Europe’s clinical trials landscape: EHA selected for ACT EU advisory group
Improving the design, efficiency and effectiveness of clinical trials is the objective of the Accelerating Clinical Trials in the European Union (ACT EU) initiative.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- »